On March 13, 2025, the Federal Circuit issued a decision in Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc., No. 23-2254 (Fed. Cir. 2025) ...

The company isn't content with just one area of focus; it's actively expanding into new verticals like injectables, peptides, ...

Violations highlight growing concerns over the unchecked rise in medicine prices and their impact on affordability ...

ET Intelligence Group: The stock of Aurobindo Pharma has lost 13% in 2025 so far, underperforming the 10% drop in the BSE ...

Telangana: Apitoria Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma, has received an Establishment ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Hyderabad: Nearly a year and a half after its subsidiary, Auro Vaccines Pvt Ltd, inked a licensing pact with Hilleman ...

On March 13, 2025, the Federal Circuit decided in Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc. (No. 2023-2254) how ...

Aurobindo Pharma rose 1.82% to Rs 1,157.90 after its subsidiary, Apitoria Pharma, received an establishment inspection report (EIR) from the U.S. Food and Drug Administration for its active ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...